Terms: = Lymphoma AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Treatment
273 results:
1. Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach.
Qadir MI; Ahmed B; Hussain N
Crit Rev Immunol; 2024; 44(5):41-50. PubMed ID: 38618727
[TBL] [Abstract] [Full Text] [Related]
2. The mechanisms behind the dual role of long non-coding RNA (lncRNA) metastasis suppressor-1 in human tumors: Shedding light on the molecular mechanisms.
Abdullaev B; Alsaab HO; Hjazi A; Alkhafaji AT; Alawadi AH; Hamzah HF
Pathol Res Pract; 2024 Apr; 256():155189. PubMed ID: 38452581
[TBL] [Abstract] [Full Text] [Related]
3. MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.
Wang X; Shi Y; Shi H; Liu X; Liao A; Liu Z; Orlowski RZ; Zhang R; Wang H
J Exp Clin Cancer Res; 2024 Mar; 43(1):68. PubMed ID: 38439082
[TBL] [Abstract] [Full Text] [Related]
4. Dissecting the genome sequence of a clinical isolated Cunninghamella bertholletiae Z2 strain with rich cytochrome P450 enzymes (Article).
Zhou EM; Chen XA; Zhou MM; Xu LY; Wang D; Shen HP; Xu WQ
Infect Genet Evol; 2024 Jun; 120():105575. PubMed ID: 38403034
[TBL] [Abstract] [Full Text] [Related]
5. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I; Boer JM; van de Ven C; Reichert CEJ; Boeree A; Kruisinga B; de Groot-Kruseman HA; Escherich G; Sijs-Szabo A; Rijneveld AW; den Boer ML
Blood Adv; 2024 Apr; 8(8):1835-1845. PubMed ID: 38386975
[TBL] [Abstract] [Full Text] [Related]
6. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
7. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
Bastian L; Beder T; Barz MJ; Bendig S; Bartsch L; Walter W; Wolgast N; Brändl B; Rohrandt C; Hansen BT; Hartmann AM; Iben K; Das Gupta D; Denker M; Zimmermann J; Wittig M; Chitadze G; Neumann M; Schneller F; Fiedler W; Steffen B; Stelljes M; Faul C; Schwartz S; Müller FJ; Cario G; Harder L; Haferlach C; Pfeifer H; Gökbuget N; Brüggemann M; Baldus CD
Blood; 2024 Apr; 143(14):1391-1398. PubMed ID: 38153913
[TBL] [Abstract] [Full Text] [Related]
8. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G; Tarantelli C; Spriano F; Gaudio E; Cascione L; Mascia M; Barreca M; Arribas AJ; Licenziato L; Golino G; Ferragamo A; Pileri S; Damia G; Zucca E; Stathis A; Politz O; Wengner AM; Bertoni F
Br J Haematol; 2024 Jan; 204(1):191-205. PubMed ID: 38011941
[TBL] [Abstract] [Full Text] [Related]
9. Differential expression of BCL11b and cdkn2a in CD30-positive peripheral T cell lymphoma: Retrospective study.
Wang Y; Zhang F; Gao N; Bu P; Cui W; Xi Y
Medicine (Baltimore); 2023 Nov; 102(46):e35531. PubMed ID: 37986346
[TBL] [Abstract] [Full Text] [Related]
10. Adolescent and young adult Hodgkin lymphoma patients at risk for subcutaneous fat gain during early cancer treatment: a brief report.
Wooten SV; Amini B; Roth M; Leung CH; Wang J; Hildebrandt MAT; Kleinerman E
Leuk Lymphoma; 2024 Jan; 65(1):62-68. PubMed ID: 37878765
[TBL] [Abstract] [Full Text] [Related]
11. Genes of Predisposition to Childhood Beta-Cell Acute Lymphoblastic Leukemia in the Kazakh Population.
Svyatova G; Boranbayeva R; Berezina G; Manzhuova L; Murtazaliyeva A
Asian Pac J Cancer Prev; 2023 Aug; 24(8):2653-2666. PubMed ID: 37642051
[TBL] [Abstract] [Full Text] [Related]
12.
Al-Zayan NR; Ashour MJ; Abuwarda HN; Sharif FA
Pediatr Hematol Oncol; 2024; 41(2):103-113. PubMed ID: 37578068
[TBL] [Abstract] [Full Text] [Related]
13. Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC.
Lara-Mejía L; Cardona AF; Mas L; Martin C; Samtani S; Corrales L; Cruz-Rico G; Remon J; Galvez-Nino M; Ruiz R; Rios-Garcia E; Tejada F; Lozano-Vazquez N; Rosell R; Arrieta O
J Thorac Oncol; 2024 Jan; 19(1):119-129. PubMed ID: 37572870
[TBL] [Abstract] [Full Text] [Related]
14. Performance of an automated registration-based method for longitudinal lesion matching and comparison to inter-reader variability.
Huff DT; Santoro-Fernandes V; Chen S; Chen M; Kashuk C; Weisman AJ; Jeraj R; Perk TG
Phys Med Biol; 2023 Aug; 68(17):. PubMed ID: 37567220
[No Abstract] [Full Text] [Related]
15. treatment of older patients with mantle cell lymphoma in the era of novel agents.
Rozental A; Jim HSL; Extermann M
Leuk Lymphoma; 2023 Sep; 64(9):1514-1526. PubMed ID: 37357622
[TBL] [Abstract] [Full Text] [Related]
16. Association of cdkn2a/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children.
Ruan Y; Xie L; Zou A
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10841-10850. PubMed ID: 37314514
[TBL] [Abstract] [Full Text] [Related]
17. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL; Brown F; Long M; Weigel C; Koirala S; Chung JH; Pray B; Villagomez L; Hinterschied C; Sircar A; Helmig-Mason J; Prouty A; Brooks E; Youssef Y; Hanel W; Parekh S; Chan WK; Chen Z; Lapalombella R; Sehgal L; Vaddi K; Scherle P; Chen-Kiang S; Di Liberto M; Elemento O; Meydan C; Foox J; Butler D; Mason CE; Baiocchi RA; Alinari L
Blood; 2023 Sep; 142(10):887-902. PubMed ID: 37267517
[TBL] [Abstract] [Full Text] [Related]
18. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Johnson WT; Ganesan N; Epstein-Peterson ZD; Moskowitz AJ; Stuver RN; Maccaro CR; Galasso N; Chang T; Khan N; Aypar U; Lewis NE; Zelenetz AD; Palomba ML; Matasar MJ; Noy A; Hamilton AM; Hamlin P; Caron PC; Straus DJ; Intlekofer AM; Lee Batlevi C; Kumar A; Owens CN; Sauter CS; Falchi L; Lue JK; Vardhana SA; Salles G; Dogan A; Schultz ND; Arcila ME; Horwitz SM
Blood Adv; 2023 Sep; 7(17):5172-5186. PubMed ID: 37078708
[TBL] [Abstract] [Full Text] [Related]
19. Optical Genome Mapping Reveals and Characterizes Recurrent Aberrations and New Fusion Genes in Adult ALL.
Vieler LM; Nilius-Eliliwi V; Schroers R; Vangala DB; Nguyen HP; Gerding WM
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980958
[TBL] [Abstract] [Full Text] [Related]
20. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract] [Full Text] [Related]
[Next]